Title: Spectrum of Primary Pulmonary Neuroendocrine Tumors from A Regional Cancer Center in South India
Authors: Dr Usha Amirtham, Dr Nikita J.Mulchandani, Dr Premalata C.S., Dr Shankar Anand Bharatnur, Dr Rekha V.Kumar
DOI: https://dx.doi.org/10.18535/jmscr/v5i7.114
Abstract
Objectives: To determine the clinico-pathologic features of pulmonary neuroendocrine tumors (NET) in a regional cancer center in South India.
Methods: 89 cases of NETs were identified over a 5-year period from May 2011 to May 2016. The clinico-pathologic and immunophenotypic features of these tumors were analyzed on needle core biopsies and they were classified according to the 2015 World Health Organization Classification of tumors of lung. Cases on which the diagnosis was made on cell blocks of aspirated material were excluded.
Results: There were 89 cases of NETs, of which 72 (81%) had lung biopsies and 17 (19%) had biopsies from metastatic sites. Among the NETs, 10 (11.2%) were carcinoid tumors and 79 were neuroendocrine carcinomas (88.8%). Of the 79 cases of neuroendocrine carcinomas, 65 (82%) were small cell lung cancers and 14 (17%) were possible large cell neuroendocrine carcinomas. The mean ages for pulmonary carcinoid and NEC were 44.5 years and 55.5 years respectively. The male to female ratio was 1.5:1 in case of pulmonary carcinoids and 7.9:1 in case of NECs. While 3 (30%) pulmonary carcinoids were central in location, 7 (70%) were peripheral and whereas 16 (20.3%) NECs were central in location, 46 (58.2%) were peripheral. Also, 17 (21.5%) cases presented with metastases in various sites which included cervical and supraclavicular lymph nodes, liver, brain, abdominal wall and bone.
Conclusion: Our study was an attempt to analyze the histopathological spectrum of pulmonary NETs, the first of its kind in the Indian literature. We noted marked preponderance of small cell neuroendocrine carcinomas amongst all NETs.
References
1. Fisseler-Eckhoff A, Demes M. Neuroendocrine Tumors of the Lung. Cancers. 2012;4(3):777-798.
2. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: International Agency for Research on Cancer, 2015.
3. Travis WD, Brambilla E, Muller-Hermelink HK et al. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC 2004.
4. Travis W, Brambilla E, Nicholson A, Yatabe Y, Austin J, Beasley M et al. The 2015 World Health Organization Classification of Lung Tumors. Journal of Thoracic Oncology 2015;10(9):1243-1260.
5. Maggard MA, O’Connell JB, Ko CY. Updated Population-Based Review of Carcinoid Tumors. Annals of Surgery. 2004;240(1):117-122.
6. Hendifar A, Marchevsky A, Tuli R. Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease. Journal of Thoracic Oncology. 2017;12(3):425-436.
7. Thomas R, Christopher DJ, Balamugesh T, Shah A. Clinico-pathologic study of pulmonary carcinoid tumours–A retrospective analysis and review of literature. Respiratory medicine. 2008;102(11):1611-4.
8. Hurt R, Bates M. Carcinoid tumors of the bronchus: a 33-year experience. Thorax. 1984; 39:617e23.
9. Harpole DH, Feldman JM, Buchanan S, Young WG, Wolfe WG. Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg. 1992;54:50e5.
10. Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazer M, et al. Pulmonary carcinoid presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. 2001;119:1647e51.
11. W. D. Travis. Advances in neuroendocrine lung tumors. Ann Oncol. 2010;21(7):65-71.
12. Devessa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005; 117:294-9
13. Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F. Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy. Journal of Thoracic Oncology. 2015 Aug 31;10(8):1133-41.